CNBX

Cannabics Pharmaceuticals Inc. [CNBX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CNBX Stock Summary

In the News

09:41 29 Mar 2024 CNBX

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19 th.

12:49 29 Mar 2024 CNBX

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients. These patent applications are now part of the Cannabics growing IP portfolio comprising of eight patent families with five granted patents and 19 pending applications.

09:05 29 Mar 2024 CNBX

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

09:25 29 Mar 2024 CNBX

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website.

09:15 29 Mar 2024 CNBX

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.

09:20 29 Mar 2024 CNBX

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.

08:25 29 Mar 2024 CNBX

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.

08:00 29 Mar 2024 CNBX

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD.

07:35 29 Mar 2024 CNBX

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board.

08:50 29 Mar 2024 CNBX

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.

CNBX Financial details

Company Rating
Neutral
Market Cap
426.23K
Income
-3.55M
Revenue
499.6K
Book val./share
-0.08
Cash/share
0
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
14 Apr 2024
P/E
0
Forward P/E
-
PEG
-
P/S
1.14
P/B
-
P/C
-
P/FCF
-4.15
Quick Ratio
0.09
Current Ratio
0.09
Debt / Equity
-0.63
LT Debt / Equity
-
-
-
EPS (TTM)
-66.36
EPS next Y
-
EPS next Q
1.34
EPS this Y
-86.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
110.85%
Revenue Q/Q
-10.56%
EPS Q/Q
-99.99%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
0%
Inst Trans
0%
ROA
-1705%
ROE
430%
ROC
-0.73%
Gross Margin
100%
Oper. Margin
357%
Profit Margin
-2075%
Payout
-
Shs Outstand
31.11M
Shs Float
31.11M
-
-
-
-
Target Price
-
52W Range
0.01-0.1
52W High
-
52W Low
-
RSI
55.51
Rel Volume
0.04
Avg Volume
265.41K
Volume
10.21K
Perf Week
6%
Perf Month
13.57%
Perf Quarter
9.66%
Perf Half Y
-24.29%
-
-
-
-
Beta
0.823
-
-
Volatility
0%, 0%
Prev Close
13.57%
Price
0.0159
Change
13.57%

CNBX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-08-31

Metric History 2019-08-312020-08-312021-08-312022-08-31 2023-08-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.0100.020.05
Net income per share
1.03-2.78-2.16-3.08-0.42
Operating cash flow per share
-2.8-2.47-2.16-1.37-0.01
Free cash flow per share
-3-2.54-2.16-1.37-0.01
Cash per share
3.190.691.20.10.01
Book value per share
13.361.571.56-1.34-0.23
Tangible book value per share
9.861.571.56-1.34-0.23
Share holders equity per share
13.361.571.56-1.34-0.23
Interest debt per share
0.020.010.761.440.15
Market cap
34.44M25.7M23.55M4.16M149.14K
Enterprise value
34.17M24.92M23.03M5.8M1.36M
P/E ratio
30.39-8.26-9.46-1.1-0.04
Price to sales ratio
3.5K3.59K0138.760.36
POCF ratio
-11.13-9.26-9.45-2.48-1.33
PFCF ratio
-10.4-9.01-9.44-2.47-1.33
P/B Ratio
2.3414.5613.04-2.55-0.07
PTB ratio
2.3414.5613.04-2.55-0.07
EV to sales
3.47K3.48K0193.543.32
Enterprise value over EBITDA
-11.04-3.44-7.32-1.67-1.65
EV to operating cash flow
-11.04-8.98-9.24-3.45-12.11
EV to free cash flow
-10.32-8.74-9.24-3.45-12.11
Earnings yield
0.03-0.12-0.11-0.91-24.88
Free cash flow yield
-0.1-0.11-0.11-0.4-0.75
Debt to equity
000.48-1.08-0.67
Debt to assets
000.282.172.69
Net debt to EBITDA
0.090.110.16-0.47-1.47
Current ratio
9.812.041.250.080.09
Interest coverage
-180.05-374.21-1.09K-2.32K-793.34
Income quality
-2.730.370.780.450.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
150.52182.78058.572.22
Research and developement to revenue
156.84235.08039.51.05
Intangibles to total assets
0.250000
Capex to operating cash flow
0.070.03000
Capex to revenue
-22.03-10.580-0.060
Capex to depreciation
-1.15-0.350-0.010
Stock based compensation to revenue
25.1310.08024.330.44
Graham number
17.579.918.719.621.47
ROIC
-0.22-0.72-0.76-23.661.36
Return on tangible assets
0.1-1.4-0.81-4.65-7.43
Graham Net
1.510.320.14-1.89-0.27
Working capital
3.87M475.12K317.8K-2.25M-2.29M
Tangible asset value
10.88M1.76M1.81M-1.63M-2.02M
Net current asset value
3.87M475.12K317.8K-2.25M-2.29M
Invested capital
000.48-1.08-0.67
Average receivables
255.87K218.4K178.34K142.57K87.69K
Average payables
265.48K223.19K204.32K319.32K398.52K
Average inventory
-1.74M-1.7M-178.34K-142.57K-87.69K
Days sales outstanding
10.55K7.77K0984.184.19
Days payables outstanding
00293.26847.8756.56
Days of inventory on hand
00-337.66-148.5-213.09
Receivables turnover
0.030.0500.374.34
Payables turnover
001.240.430.48
Inventory turnover
00-1.08-2.46-1.71
ROE
0.08-1.76-1.382.311.84
Capex per share
-0.2-0.07000

Quarterly Fundamentals Overview

Last date of statement is 2023-11-30 for Q1

Metric History 2022-11-302023-02-282023-05-312023-08-31 2023-11-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0311.330
Net income per share
-0.29-1.34-0.02-64.99-0.01
Operating cash flow per share
-0.08-0.0102.320
Free cash flow per share
-0.08-0.0102.320
Cash per share
0.020.02014.70
Book value per share
-1.57-1.02-0.21-228.6-0.08
Tangible book value per share
-1.57-1.02-0.21-228.6-0.08
Share holders equity per share
-1.57-1.02-0.21-228.6-0.08
Interest debt per share
1.413.210.14-387.380.05
Market cap
4.98M191.39K191.8K149.14333.13K
Enterprise value
6.72M1.68M1.48M1.21M1.57M
P/E ratio
-3.38-0.02-0.280-0.47
Price to sales ratio
000.6203.72
POCF ratio
-51.94-10.33-10.320.01-4.64
PFCF ratio
-51.94-10.33-10.320.01-4.56
P/B Ratio
-2.52-0.1-0.10-0.16
PTB ratio
-2.52-0.1-0.10-0.16
EV to sales
004.7712.1417.51
Enterprise value over EBITDA
-22.140.77-11.12-0.47-11.82
EV to operating cash flow
-70.09-90.82-79.6259.17-21.79
EV to free cash flow
-70.09-90.82-79.6259.17-21.43
Earnings yield
-0.07-13.71-0.9-3.85K-0.54
Free cash flow yield
-0.02-0.1-0.1137.57-0.22
Debt to equity
-0.89-0.77-0.7-0.67-0.63
Debt to assets
2.893.332.012.693.39
Net debt to EBITDA
-5.740.68-9.68-0.47-9.31
Current ratio
0.040.040.140.090.06
Interest coverage
-31.880.459.410.03-25.96
Income quality
0.270.010.12-0.040.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.711.671.67
Research and developement to revenue
000.850.931.26
Intangibles to total assets
00000
Capex to operating cash flow
00000.02
Capex to revenue
0000-0.01
Capex to depreciation
0000-0.03
Stock based compensation to revenue
000.110.350.39
Graham number
3.225.550.29578.180.1
ROIC
1.69-4.540.27-1.970.22
Return on tangible assets
-0.6-5.68-0.26-1.15-0.46
Graham Net
-2.02-1.23-0.26-267.77-0.09
Working capital
-2.48M-2.36M-2.22M-2.29M-2.33M
Tangible asset value
-1.97M-2.01M-1.91M-2.02M-2.09M
Net current asset value
-2.48M-2.36M-2.22M-2.29M-2.33M
Invested capital
-0.89-0.77-0.7-0.67-0.63
Average receivables
79.43K69.59K182.87K199.63K81.95K
Average payables
529.02K653.73K862.89K675.58K290.81K
Average inventory
-79.43K-69.59K-182.87K-199.63K-81.95K
Days sales outstanding
0088.485.1569.73
Days payables outstanding
1.24K1.58K2.28K785.42560.4
Days of inventory on hand
-162.73-136.12-685.55-221.22-158.03
Receivables turnover
001.021.061.29
Payables turnover
0.070.060.040.110.16
Inventory turnover
-0.55-0.66-0.13-0.41-0.57
ROE
0.191.30.090.280.09
Capex per share
00000

CNBX Frequently Asked Questions

What is Cannabics Pharmaceuticals Inc. stock symbol ?

Cannabics Pharmaceuticals Inc. is a US stock , located in Bethesda of Md and trading under the symbol CNBX

What is Cannabics Pharmaceuticals Inc. stock quote today ?

Cannabics Pharmaceuticals Inc. stock price is $0.0159 today.

Is Cannabics Pharmaceuticals Inc. stock public?

Yes, Cannabics Pharmaceuticals Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap